Inhibrx Pre-Tax Profit Margin 2020-2022 | INBX
Inhibrx pre-tax profit margin from 2020 to 2022. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
| Inhibrx Pre-Tax Profit Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Pre-Tax Income | Pre-Tax Margin |
| 2022-03-31 | $0.01B | $-0.09B | -1175.00% |
| 2021-12-31 | $0.01B | $-0.08B | -1025.00% |
| 2021-09-30 | $0.01B | $-0.08B | -987.50% |
| 2021-06-30 | $0.01B | $-0.08B | -709.09% |
| 2021-03-31 | $0.01B | $-0.08B | -576.92% |
| 2020-12-31 | $0.01B | $-0.08B | -584.62% |
| 2020-06-30 | $0.01B | $-0.06B | -1140.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Biomedical and Genetics | $0.452B | $0.007B |
| Inhibrx Inc. is a clinical-stage biotechnology company. The company's pipeline is focused on oncology and orphan diseases. Inhibrx Inc. is based in SAN DIEGO. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bristol Myers Squibb (BMY) | United States | $163.597B | 9.95 |
| Bio-Rad Laboratories (BIO.B) | United States | $14.907B | 32.33 |
| QIAGEN (QGEN) | Netherlands | $10.865B | 17.15 |
| Biohaven Pharmaceutical Holding (BHVN) | United States | $10.248B | 0.00 |
| Ginkgo Bioworks Holdings (DNA) | United States | $4.228B | 0.00 |
| Arcus Biosciences (RCUS) | United States | $1.901B | 48.18 |
| Emergent Biosolutions (EBS) | United States | $1.599B | 6.85 |
| Myovant Sciences (MYOV) | United Kingdom | $1.236B | 0.00 |
| Zymeworks (ZYME) | Canada | $0.320B | 0.00 |
| Gelesis Holdings (GLS) | United States | $0.114B | 0.00 |
| Enzo Biochem (ENZ) | United States | $0.104B | 0.00 |
| Ambrx Biopharma (AMAM) | United States | $0.103B | 0.00 |
| SQZ Biotechnologies (SQZ) | United States | $0.087B | 0.00 |
| ADC Therapeutics SA (ADCT) | Switzerland | $0.000B | 0.00 |
